VPIM
LIMN

Vanguard Personalized Indexing Management’s Liminatus Pharma LIMN Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio LIMN Stock Details LIMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.97K Buy
+34,706
New +$18.5K ﹤0.01% 2164

Other funds holding LIMN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Personalized Indexing Management's LIMN Position: Q1 2026 in Review

Vanguard Personalized Indexing Management opened a new position in Liminatus Pharma (LIMN) in Q1 2026: 34,706 shares worth $5.97K. The stake represents ﹤0.01% of the portfolio and ranks #2164 among its holdings.

15 funds tracked by Wall St. Rank hold LIMN as of Q1 2026.

  • Vanguard Personalized Indexing Management held 34,706 shares of Liminatus Pharma worth $5.97K as of Q1 2026.
  • Liminatus Pharma was a new Vanguard Personalized Indexing Management position in Q1 2026.
  • Liminatus Pharma made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #2164 holding.
  • 15 funds tracked by Wall St. Rank held Liminatus Pharma as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.